These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6179685)

  • 1. N-Acetylprocainamide kinetics and clinical response during repeated dosing.
    Rodman JH; Hurst A; Gaarder T; Cohen J; Jelliffe RW
    Clin Pharmacol Ther; 1982 Sep; 32(3):378-86. PubMed ID: 6179685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias.
    Atkinson AJ; Lertora JJ; Kushner W; Chao GC; Nevin MJ
    Clin Pharmacol Ther; 1983 May; 33(5):565-76. PubMed ID: 6188570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation.
    Piergies AA; Ruo TI; Jansyn EM; Belknap SM; Atkinson AJ
    Clin Pharmacol Ther; 1987 Jul; 42(1):107-12. PubMed ID: 2439251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide.
    Winkle RA; Jaillon P; Kates RE; Peters F
    Am J Cardiol; 1981 Jan; 47(1):123-30. PubMed ID: 6161534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias.
    Sung RJ; Juma Z; Saksena S
    Am Heart J; 1983 May; 105(5):811-9. PubMed ID: 6189384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torsade de pointes induced by N-acetylprocainamide.
    Chow MJ; Piergies AA; Bowsher DJ; Murphy JJ; Kushner W; Ruo TI; Asada A; Talano JV; Atkinson AJ
    J Am Coll Cardiol; 1984 Sep; 4(3):621-4. PubMed ID: 6206104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
    Funck-Brentano C; Light RT; Lineberry MD; Wright GM; Roden DM; Woosley RL
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):364-73. PubMed ID: 2476614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of N-acetylprocainamide.
    Atkinson AJ; Ruo TI
    Angiology; 1986 Dec; 37(12 Pt 2):959-67. PubMed ID: 2433970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias.
    Ludden TM; Crawford MH; Kennedy GT
    Pharmacotherapy; 1985; 5(1):11-5. PubMed ID: 2580291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions.
    Lee WK; Strong JM; Kehoe RF; Dutcher JS; Atkinson AJ
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):508-14. PubMed ID: 776488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias.
    Kluger J; Drayer D; Reidenberg M; Ellis G; Lloyd V; Tyberg T; Hayes J
    Am J Cardiol; 1980 Jun; 45(6):1250-7. PubMed ID: 6155064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretical basis for interest in acetylprocainamide and clinical experiences with this new antiarrhythmic agent.
    Drayer D; Kluger J; Reidenberg M; Lahita R
    Drug Metab Rev; 1979; 10(2):239-46. PubMed ID: 95247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Acetylprocainamide kinetics after single and repeated oral doses.
    Ludden TM; Crawford MH
    Clin Pharmacol Ther; 1982 Mar; 31(3):343-9. PubMed ID: 6174262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease.
    Wynn J; Miura DS; Torres V; Flowers D; Keefe D; Williams S; Somberg JC
    Am J Cardiol; 1985 Nov; 56(13):877-81. PubMed ID: 2414983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions.
    Atkinson AJ; Lee WK; Quinn ML; Kushner W; Nevin MJ; Strong JM
    Clin Pharmacol Ther; 1977 May; 21(5):575-87. PubMed ID: 322922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arrhythmia control by selective lengthening of cardiac repolarization: role of N-acetylprocainamide, active metabolite of procainamide.
    Singh BN; Feld G; Nademanee K
    Angiology; 1986 Dec; 37(12 Pt 2):930-8. PubMed ID: 2433967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.
    Giardina EG
    Ann N Y Acad Sci; 1984; 432():177-88. PubMed ID: 6084435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.
    Harron DW; Brogden RN
    Drugs; 1990 May; 39(5):720-40. PubMed ID: 1693889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.